

AVOIDED COST STUDY OF DRUGS IN CLINICAL TRIALS AT A TERTIARY HOSPITAL


A. Henares López, J.C. Del Río Valencia, R. Tamayo Bermejo, M.A. Rosado Souviron, I. Muñoz Castillo
Hospital Regional Universitario de Málaga, Hospital Pharmacy, Málaga, Spain.

Objectives


To determine the avoided cost attributable to supplied drugs by clinical trials (CT) of Oncology during one year.

Methods or Study Design


Observational, retrospective study




Results:




Avoided cost: €3,482,662



Total cost: €5,595,340



Most prevalent pathologies



Conclusions

The CT are an opportunity to contain pharmaceutical costs in hospitals. Patients in CT produced a cost saving of € 3,482,662/year. The potential savings justify the need to incorporate as many clinical trials as possible, not just for cost savings but because it would mean better access for patients to these highly effective and/or breakthrough therapies.

